Last updated: September 2, 2026
Sargramostim, marketed in the United States as Leukine by Partner Therapeutics, is a mature granulocyte-macrophage colony-stimulating factor biologic with a specialized commercial position. Its original oncology markets face competition from filgrastim and pegfilgrastim products, while its radiation-countermeasure indication and potential use in cell therapy create narrower growth opportunities. Public financial disclosures are limited because Partner Therapeutics is privately held, so product-level revenue and profitability are not reported.
What is sargramostim and how is it used?
Sargramostim is recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF. It is produced in a yeast expression system and stimulates the proliferation and differentiation of hematopoietic progenitor cells.
The FDA-approved Leukine label covers several clinical settings:
| Indication |
Commercial relevance |
| Acute myeloid leukemia after induction chemotherapy |
Supports neutrophil recovery and reduces infection-related complications |
| Autologous or allogeneic bone-marrow transplantation |
Accelerates myeloid reconstitution |
| Peripheral blood progenitor-cell mobilization |
Used to increase collection of hematopoietic progenitor cells |
| Hematopoietic reconstitution after myeloablative therapy |
Institutional transplant market |
| Hematopoietic acute radiation syndrome |
Government and emergency-preparedness market |
Leukine is supplied in injectable formulations, including liquid and lyophilized presentations. The product is administered subcutaneously or intravenously, depending on the indication and formulation. The FDA approved sargramostim in 1991, making it one of the earliest recombinant hematopoietic growth factors in commercial use.[1]
How large is the sargramostim market?
Sargramostim operates in a small, segmented market rather than a broad outpatient specialty-pharmacy market. The principal revenue pools are:
- Hospital oncology and transplant use.
- Hematopoietic stem-cell mobilization.
- Government procurement for radiation emergencies.
- Institutional and investigator-sponsored use in immunology and cell therapy.
The oncology market is structurally constrained by competition from granulocyte colony-stimulating factor products. Filgrastim, pegfilgrastim, biosimilars, and tbo-filgrastim are commonly used for chemotherapy-induced neutropenia. Sargramostim has a different receptor profile and clinical positioning, but many institutions can substitute other myeloid growth factors for routine neutrophil support.
The radiation-countermeasure market is commercially distinct. Demand is driven less by recurring patient volume than by government preparedness programs, inventory requirements, shelf life, and procurement contracts. This market can produce irregular revenue, including large orders followed by periods of limited activity.
No reliable public source reports annual global Leukine revenue, Partner Therapeutics revenue, or sargramostim market share. Partner Therapeutics is privately held and does not publish a public company-style product revenue segment.
What is the financial trajectory for sargramostim?
Sargramostim’s financial trajectory is best characterized as mature base revenue with episodic upside rather than a conventional high-growth biologic profile.
Historical maturity
The product entered the market more than three decades ago. Its core oncology and transplant uses have established clinical familiarity, but long exposure to competitive growth factors limits pricing power. The product’s commercial value depends on:
- Institutional formulary status.
- Supply reliability.
- Hospital contracting.
- Reimbursement for inpatient and outpatient administration.
- Government procurement.
- Clinical differentiation in selected indications.
The long commercial history reduces development risk but also limits the potential for premium pricing based solely on molecular novelty.
Ownership transition
Sanofi transferred U.S. Leukine rights to Partner Therapeutics in 2018. Financial terms were not publicly disclosed.[2] The transaction moved the product from a large multinational portfolio to a specialized private company whose commercial strategy centers on hematology, oncology, immunology, and medical-countermeasure applications.
The ownership change gave Partner direct control over pricing, supply, lifecycle management, and government contracting. It also placed greater importance on the company’s ability to maintain manufacturing economics for a mature biologic.
Growth drivers
The strongest potential growth drivers are:
- Radiation acute-injury preparedness contracts.
- Greater use in stem-cell collection and transplantation.
- Selected AML protocols.
- Combination studies in immune-mediated disease.
- Cell-therapy manufacturing and post-treatment recovery.
- International commercialization or licensing.
The radiation indication is commercially important because it expanded Leukine beyond traditional oncology and transplantation. The FDA approved the indication in 2018 under the Animal Rule framework for patients exposed to myelosuppressive doses of radiation when conventional clinical efficacy trials cannot be conducted.[3]
Financial constraints
The main constraints are:
- Low differentiation in routine neutrophil support.
- Competition from lower-cost filgrastim and pegfilgrastim products.
- Limited public evidence of large recurring government demand.
- Manufacturing costs associated with a protein biologic.
- Lack of publicly disclosed revenue data.
- Potential payer preference for more widely used G-CSF products.
Sargramostim can generate strategic value without producing large reported sales. Government stockpiling, supply continuity, and defense-related procurement can justify continued commercialization even if ordinary hospital demand is moderate.
How does sargramostim compare with filgrastim and pegfilgrastim?
Sargramostim and filgrastim are both hematopoietic growth factors, but they are not interchangeable molecules.
| Attribute |
Sargramostim |
Filgrastim |
Pegfilgrastim |
| Growth-factor class |
GM-CSF |
G-CSF |
Long-acting G-CSF |
| Primary effect |
Broader myeloid stimulation, including granulocytes, macrophages, and dendritic-cell lineages |
Predominantly neutrophil stimulation |
Prolonged neutrophil stimulation |
| Dosing pattern |
Often daily during treatment courses |
Daily |
Usually once per chemotherapy cycle |
| Main commercial use |
AML, transplantation, progenitor-cell mobilization, radiation injury |
Chemotherapy-induced neutropenia, mobilization |
Prophylaxis of chemotherapy-induced neutropenia |
| Competitive pressure |
High in routine hospital use |
Strong generic and biosimilar pressure |
Strong biosimilar pressure |
| Government countermeasure role |
Established FDA indication for hematopoietic acute radiation syndrome |
Not positioned identically in the Leukine indication |
Not positioned identically in the Leukine indication |
Pegfilgrastim and filgrastim have a larger routine oncology market. Sargramostim’s differentiation is stronger where GM-CSF biology, radiation injury, macrophage activity, or broader myeloid recovery is clinically relevant.
What patents protect sargramostim and Leukine?
Sargramostim’s original composition and basic product patents are long expired. The product was approved in 1991, and no meaningful composition-of-matter exclusivity remains.
Orange Book status
Leukine is approved under NDA 103362. Public FDA Orange Book records should be reviewed for current listed patents and exclusivity entries, but the product’s original patent estate is not a material barrier to generic or follow-on competition.[4]
The commercial protection profile is primarily based on:
- Manufacturing know-how.
- Product quality controls.
- Regulatory experience.
- Supply reliability.
- Institutional relationships.
- Government contracting.
- Potential formulation or process patents, if separately listed or enforced.
A mature biologic can remain commercially defensible after patent expiry because manufacturing a consistent recombinant protein requires validated cell-line, purification, analytical, and fill-finish capabilities. Those barriers are meaningful but generally weaker than enforceable composition patents.
Formulation and method-of-use protection
Any surviving protection would be more likely to involve formulation, manufacturing, dosing, or a specific method of use than the sargramostim molecule itself. The FDA radiation indication provides regulatory differentiation, but an approved indication does not by itself prevent off-label use of competing products.
Method-of-use patents would have to be evaluated claim by claim. A patent covering use in hematopoietic acute radiation syndrome could create litigation exposure for a competitor seeking a label that includes the same indication. It would not necessarily block all off-label use or all sargramostim competition.
When does sargramostim lose exclusivity?
Sargramostim has already lost its core patent exclusivity. The relevant competitive question is not the expiration of a single basic patent but the timing of follow-on biologic entry and the scope of any remaining listed patents.
FDA regulatory exclusivity associated with the original 1991 approval has expired. The 2018 radiation indication may have generated indication-specific regulatory benefits, but it does not recreate composition-of-matter exclusivity for the entire product.
No FDA-approved sargramostim biosimilar was publicly identified in the FDA Purple Book through June 2024.[5] A follow-on applicant could pursue a 351(k) biosimilar pathway or a different biologic route, subject to analytical comparability, clinical requirements, manufacturing validation, and any applicable patent certifications.
Which companies are challenging sargramostim?
No major publicly documented Paragraph IV litigation campaign against Leukine was identified through June 2024. The absence of litigation does not indicate that the product is strongly patent-protected. It is more consistent with a relatively small market, limited public Orange Book barriers, and the economics of developing a competing biologic.
Potential competitive groups include:
- Biosimilar manufacturers with recombinant protein capabilities.
- Existing hematology suppliers.
- Specialty injectable manufacturers.
- Contract manufacturers seeking a 351(k) or standalone biologic product.
- Companies with G-CSF portfolios that could compete for institutional protocols.
The commercial hurdle is not only patent clearance. A competitor would need to secure FDA approval, demonstrate consistent supply, obtain hospital formulary access, and compete against established G-CSF alternatives.
What is the FDA regulatory status of Leukine?
Leukine has full FDA approval for its labeled indications. The radiation injury indication was approved under the Animal Rule because controlled human efficacy studies are not feasible for that condition.[3]
The regulatory position is commercially useful for government procurement because it provides an FDA-labeled countermeasure indication rather than relying solely on off-label use. The label also supports continued hospital use in AML, transplantation, and progenitor-cell mobilization.
Sargramostim is not a monoclonal antibody or complex targeted biologic. Biosimilar development may therefore be technically more manageable than development of a highly heterogeneous antibody, although the product still requires robust characterization and manufacturing controls.
What licensing deals affect sargramostim?
The key disclosed commercial transaction is Sanofi’s 2018 transfer of Leukine rights to Partner Therapeutics.[2] Public reporting did not disclose the purchase price, milestone structure, royalty rate, or minimum purchase obligations.
The transaction suggests that the asset was valued for its established approval base, manufacturing platform, and strategic position in radiation preparedness rather than for near-term patent exclusivity. Any external licensing or government procurement arrangements should be analyzed separately because terms may not be public.
What generic launch risks exist for sargramostim?
Near-term risk
The near-term risk from an approved biosimilar appears limited by the lack of a publicly identified approved competitor through June 2024. However, the product’s mature status makes future entry economically plausible.
Medium-term risk
A biosimilar or follow-on sargramostim could pressure price and hospital contracting if it has:
- A lower acquisition cost.
- Reliable supply.
- Broad payer coverage.
- Interchangeability or favorable substitution treatment.
- A label covering the highest-value indications.
Launch scenarios
| Scenario |
Likely market effect |
| No approved follow-on |
Partner retains niche pricing and government-contracting position |
| One biosimilar entrant |
Moderate hospital price pressure; limited impact in radiation stockpile contracts |
| Multiple entrants |
Significant erosion in routine oncology and transplant use |
| Follow-on with radiation indication |
Greater pressure on Leukine’s strategic differentiation |
| Manufacturing disruption |
Temporary pricing power for the incumbent if supply is constrained |
The highest-risk segment is routine hospital use. The lower-risk segment is government procurement, where regulatory qualification, inventory validation, and supply continuity can matter more than nominal unit price.
How strong is the sargramostim patent estate?
Sargramostim has a weak traditional patent estate but a potentially defensible commercial platform.
| Protection category |
Assessment |
| Composition patents |
Expired |
| Original regulatory exclusivity |
Expired |
| Basic formulation protection |
Limited or expired based on the product’s age |
| Method-of-use patents |
Potentially relevant for specific indications |
| Manufacturing know-how |
Important practical barrier |
| FDA radiation indication |
Regulatory differentiation, not molecule-wide exclusivity |
| Government relationships |
Commercial barrier that may be difficult to replicate quickly |
| Brand and clinical familiarity |
Moderate institutional barrier |
The patent estate should therefore be rated as weak for blocking competition and moderate for supporting commercial continuity. The strongest defenses are operational and regulatory, not molecular.
What is the geographic coverage and international opportunity?
The United States is the most strategically important market because it includes the FDA-approved radiation-countermeasure indication and established government preparedness infrastructure.
International opportunities depend on:
- Local approval of sargramostim.
- Hospital adoption in oncology and transplantation.
- Reimbursement for inpatient biologic administration.
- Availability of lower-cost G-CSF alternatives.
- Government interest in radiation preparedness.
- Local manufacturing and procurement rules.
The product’s commercial performance outside the United States is difficult to quantify because Partner Therapeutics does not publish a detailed geographic revenue breakdown. International growth would likely require licensing or distributor partnerships rather than a large direct commercial buildout.
What patent litigation and settlement agreements affect Leukine?
No major publicly reported patent litigation or Paragraph IV settlement involving Leukine was identified through June 2024. No public settlement appears to establish a delayed generic-entry date.
That litigation profile differs from newer biologics with dense patent thickets. For sargramostim, the principal legal issues are more likely to involve:
- FDA approval pathway.
- Patent scope for specific indications.
- Manufacturing and process claims.
- Procurement agreements.
- Trade secrets.
- Contractual rights following the Sanofi-to-Partner transaction.
Key Takeaways
- Sargramostim is a mature GM-CSF biologic with FDA approval dating to 1991.
- Leukine’s core patent and regulatory exclusivity have expired.
- Partner Therapeutics acquired U.S. Leukine rights from Sanofi in 2018 under undisclosed financial terms.
- Routine oncology use faces strong competition from filgrastim, pegfilgrastim, and biosimilars.
- The 2018 hematopoietic acute radiation syndrome indication is the product’s main strategic differentiator.
- Government procurement can create episodic revenue but is difficult to forecast from public information.
- Partner Therapeutics is private and does not report product-level revenue, margins, or sales guidance.
- No approved sargramostim biosimilar or major Paragraph IV litigation was publicly identified through June 2024.
- Commercial protection rests more on manufacturing, regulatory status, supply, and government relationships than on patents.
- The most credible financial outlook is stable niche revenue with event-driven upside and long-term follow-on biologic risk.
FAQs
Is sargramostim interchangeable with filgrastim?
No. Sargramostim is a GM-CSF product, while filgrastim is a G-CSF product. They have different receptor activity, labeling, dosing, and clinical positioning.
Can sargramostim be used after CAR-T therapy?
Use in cell-therapy settings depends on the treatment protocol and institutional practice. Sargramostim is not universally established as a standard post-CAR-T product, and safety considerations must be evaluated for each protocol.
Does Leukine have an orphan-drug monopoly for radiation injury?
The radiation indication is FDA-approved under the Animal Rule, but the approval does not create permanent molecule-wide exclusivity. Any indication-specific exclusivity or patent protection must be assessed using current FDA and patent records.
Why has no major sargramostim biosimilar launched?
The addressable market is narrower than the market for filgrastim or pegfilgrastim, while approval still requires complex biologic manufacturing, clinical development, and hospital commercialization. The expected return may not justify development for many manufacturers.
Could government stockpiling materially increase Leukine revenue?
Yes. Large preparedness purchases could materially affect annual sales because government demand is irregular and contract-driven. The impact would depend on procurement volume, contract duration, inventory requirements, and pricing.
References
- U.S. Food and Drug Administration. (2023). Leukine (sargramostim) prescribing information.
- Partner Therapeutics. (2018). Partner Therapeutics acquires Leukine from Sanofi. Company announcement.
- U.S. Food and Drug Administration. (2018). FDA approves Leukine for hematopoietic acute radiation syndrome.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
